MEM.AX up 40% intraday on ASX 03 Feb 2026: watch A$0.01 forecast upside

Memphasys Limited (MEM.AX stock) leads small-cap gainers intraday on ASX, trading up 40.00% to A$0.007 on 03 Feb 2026. Volume is heavy at 11,636,947.00 shares versus an average of 4,423,749.00, signalling speculative interest. The jump follows renewed attention to Memphasys’ fertility device pipeline and micro-cap positioning within the Australian biotechnology sector. We examine the drivers, valuation signals and short-term technical targets to explain why MEM.AX stock is a top gainer and what investors should watch next.

Intraday movers: MEM.AX stock

MEM.AX stock is trading at A$0.007 on the ASX, up 40.00% intraday from a previous close of A$0.005. Daily range is A$0.006–A$0.007, with market capitalisation about A$18,810,610.00 and 2,687,230,000.00 shares outstanding. Elevated volume at 11,636,947.00 shares is 2.63x the average, indicating momentum-driven buying rather than steady accumulation.

News and drivers: MEM.AX stock

Price action appears driven by renewed attention to Memphasys’ IVF-focused Felix device and pipeline updates that can affect commercial adoption. There is no formal earnings release today; the next earnings announcement is scheduled for 26 Feb 2026. Media and sector flows in healthcare biotech are lifting small-cap names; broader Asian markets and commodity moves may be supporting risk appetite today source and Reuters commentary on market tone also lifted sentiment source.

Valuation snapshot: MEM.AX stock

Memphasys shows early-stage biotech metrics. Key ratios: Price to Sales 35.70, Price to Book 2.59, Debt to Equity 0.95, and Current Ratio 0.25. Trailing EPS is not available and P/E is not meaningful. Operating cash flow per share is negative at -0.00121 and free cash flow per share is -0.00121, underscoring limited near-term free cash generation. These figures point to a high-risk, speculative valuation profile for MEM.AX stock.

Technical view and price targets: MEM.AX stock

Momentum is strong: RSI is 56.62 and ADX reads 38.27, indicating a trending move. Short-term resistance sits at the year high A$0.011 and intraday high A$0.007. We set a conservative near-term upside target of A$0.012 (bull case) and a downside risk level at A$0.004 (bear case). Traders should watch volume and whether MEM.AX stock holds above A$0.006 for confirmation.

Meyka AI grade and forecast: MEM.AX stock

Meyka AI rates MEM.AX with a score of 58.76 out of 100 (Grade C+, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of A$0.010, implying an upside of 42.86% versus the current A$0.007. The model’s yearly projection is A$0.00287, implying downside risk versus today. Forecasts are model-based projections and not guarantees, and they reflect high volatility in micro-cap biotech names.

Risks and opportunities: MEM.AX stock

Opportunity: commercial traction for Felix or a licensing deal could re-rate MEM.AX stock rapidly given its small market cap and product leverage. Risk: low liquidity, negative operating cash flow, weak current ratio and extended receivables present balance-sheet constraints. Institutional coverage is limited and company fundamentals show stretched working capital metrics, making MEM.AX stock sensitive to any funding or trial setbacks.

Final Thoughts

MEM.AX stock is an intraday top gainer on ASX on 03 Feb 2026, rising 40.00% to A$0.007 on heavy volume. The move reflects speculative buying tied to Memphasys’ fertility device pipeline and sector momentum. Valuation metrics show a high price-to-sales ratio (35.70) and tight liquidity with a current ratio of 0.25, so gains can reverse quickly if news flow stalls. Meyka AI’s forecast model projects a near-term monthly price of A$0.010, an implied upside of 42.86% versus today, but also a year projection of A$0.00287 that highlights downside risk. Our technical targets are A$0.012 (bull) and A$0.004 (bear). Investors should treat MEM.AX as speculative, watch trading volume, and track upcoming announcements. For a real-time quote and deeper data, see the Meyka stock page for MEM.AX stock at Meyka AI stock page. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.